Global Markets and Technologies for Advanced Drug Delivery Systems

New York, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Markets and Technologies for Advanced Drug Delivery Systems" - https://www.reportlinker.com/p01940407/?utm_source=GNW
The geographic scope of this study covers the U.S. and companies worldwide. The report identifies the main elements of advanced drug delivery products and trends in different types of industries.

Report Includes:
- 62 data tables 62 additional tables
- An overview of the global markets and technologies for advanced drug delivery systems
- Analyses of global market trends, with data from 2018, 2019, estimates for 2020 and projections of compound annual growth rates (CAGRs) through 2025
- A look into the current state, setbacks, innovations, and future trends, and coverage of clinical trials in drug delivery systems
- Discussion on the different categories of drug delivery, and details of acquisitions, mergers, and alliances by companies and global organizations
- Description of advanced immediate-release technology and delayed release and pulsatile release drug delivery technology
- Information on monoclonal antibodies (MAbs), Prodrugs and other drug carriers of advanced drug delivery systems
- Insights of the regulatory environment, and the technology involved, including the latest trends and developments
- Company profiles of major players including Alcon, Bausch & Lomb, Baxter International Inc., Eisai Co. Ltd., GlaxoSmithKline PLC, Eli Lilly, Novartis and Sanofi

Summary:
Drug delivery refers to technologies, formulations based on drug vehicles or carriers, and approaches (routes of administration) used to deliver drugs for various applications or therapeutic use.

Advanced drug delivery systems (ADDS) refer to the technologies used for controlling the rate of drug release. The type of technology used greatly depends on the type of disease, type of drug and desired effect.

Advanced formulations and use of novel drug vehicles have proven to increase the efficiency and efficacy of drug delivery systems, resulting in better treatment outcomes. Moreover, ADDS have become the holy grail in the treatment of several diseases and in unlocking the potential and value of pharma’s existing compounds, as well as in exploring the potential of several new compounds, including ones that don’t make it to market due to their limitations or issues related to factors such as adsorption, solubility, toxicity, molecular weight, metabolism, distribution and excretion.

Although the quest for advanced drug delivery systems and formulations began long ago, ADDS have gained more momentum in the past few decades with the development and advancement of formulations and technologies such as modified-release technologies, targeted-release technologies and formulations based on nanoparticles, microparticles, polymer conjugates, interfering RNA (siRNA), monoclonal antibodies, intelligent/smart polymers, osmotically modulated drug delivery, liposomes and dendrimers.

Currently, the global ADDS market is valued at $REDACTED and is expected to reach at least $REDACTED in the next five years .The market is not expected to saturate any time soon, but rather should be boosted by patent expiries, targeted drug delivery systems, cell therapy, nanotechnology and biologics, which are expected to open up new opportunities for this market.

The COVID-19 pandemic is also fueling R&D and the ADDS market overall.

Advanced drug delivery is an attractive industry with multifaceted growth opportunities in research and development, technologies, applications, and formulations.

Market analysis based on drug release mechanism shows that controlled-release and targeted-release formulations command the largest share of the market, and this is anticipated to remain the same over the next five years.Market analysis by route of administration clearly suggests that oral route administration and oral dosage forms dominate the market.

The injectable sector is also expanding. To stay competitive, product differentiation is critical and demands high priority.

Oncology is the largest application area in the advanced drug delivery market due to the increasing use of new drug carriers and materials in targeted-release and controlled-release drug delivery, which has led to better drug formulations meeting unmet market needs. The COVID-19 pandemic is also fueling new developments in the respiratory sector.
Read the full report: https://www.reportlinker.com/p01940407/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________